Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only if they don't appointment an independent director within the next 12 months.
"Under Listing Rules 5605(b)(1)(A) and 5605(c)(4), Nasdaq shall provide the Company with time to regain compliance either until the earlier of its next annual meeting or March 30, 2018; or if the next annual meeting is before September 26, 2017, until September 26, 2017."
Almost sounds to me like you're hoping to tank the stock. Have you shorted it?
Unfortunately, through his silence JJ has abdicated control of the company's future to rumor and speculation.
I think you're confusing trademarks with patents. Trademarks protect the name not the technology. There is no inherent value to the name "FanPass," just as there is no inherent value to the name "Apple." The value is in the technology.
From what I understand, Aethlon doesn't have visibility of the data until DaVita submits the report. That said, I don't recall Aethlon has ever hosted a shareholder meeting outside of San Diego. I think the fact that they are having it in Houston this year telegraphs that JJ expects the data to be made public on or prior to March 30. Personally, I'm very excited about what might be going on behind the scenes in preparation for the Houston meeting. This could be Aethlon's moment.
Refreshing to read such a thoughtful post on this board. Thank you.
Completely worthless. That's a Google return on someone's opinion posted to Investorvillage.
DARPA
It's worth noting that if Aethlon is going to get a follow-on contract for the DLT program, it should be this week or next. DARPA awarded or extended the original contract on the following dates: Last extension, Sept. 25, 2015; third extension, Sept. 22, 2014; second extension, Sept. 26, 2013; first extension, Aug. 21, 2012; and initial award, Oct. 3, 2011.
Their August filings for 10-Qs have landed typically in thed two-week window between the 5th of the month and the 20th.
I'll be curious to see what effect this will have on Aethlon and ESI:
Today, the U.S. Food and Drug Administration released a draft guidance document, "Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product." This draft guidance is a “how-to” guide to supplement previously released final guidance “In Vitro Companion Diagnostic Devices,” which defined in vitro companion diagnostic devices (IVD companion diagnostics) and set the expectation that IVD companion diagnostics and corresponding therapeutic products should be approved or cleared by the FDA at the same time.
This draft guidance provides general principles for addressing issues that may arise when codeveloping a therapeutic product and a corresponding IVD companion diagnostic. It also provides considerations for planning and executing clinical trials and successfully fulfilling FDA regulatory requirements.
This guidance is part of the FDA’s efforts to facilitate innovation in precision medicine by assisting with the codevelopment of therapeutic products and companion diagnostics. We welcome comments regarding this draft guidance. The notice of availability published in the Federal Register and will be open for 90 days from that date.
In addition, on August 18, the FDA will host a webinar to share information and answer questions about the draft guidance. More information about the webinar is available at http://www.fda.gov/CDRHwebinar.
Excellent. Thanks.
Three-year-old news. What was the context of why he posted it?
No bearing. Malaria is a parasite not a virus.
ClinicalTrials.gov is now up to date with the latest info on the HepC trial.
https://www.clinicaltrials.gov/ct2/show/NCT02215902?term=davita+hcv&rank=2
Completion now expected in Feb. 2017.
Here's where we could see cash first: http://www.footballinjuryclaims.com/index.html
Aethlon established a relationship with DaVita two years ago (exactly two years as of yesterday, coincidentally enough). If Aethlon were looking for a partner, DaVita would be it. Their market cap is $14B and they operate more than one thousand dialysis centers across the US.
... testing it right now.
Zika. And I promise you that they are testing it right.
One share traded at $4.80. Yeah, no manipulation going on here.
Interesting. I foresee defense lawyers at the vanguard for demanding access to CTE data and diagnostic tools.
"A new method to render male mosquitoes infertile by nuclear radiation...."
What could possibly go wrong?
Mosq-zilla!
I find the timing of the investor's call to be a bit curious. It's at least a full week earlier than any 10-Q they've released in the last eight years. My guess: They're timing the release of the CTE paper with the Super Bowl and they're looking to make a pretty big splash.
JJ's pretty smart. I can promise you that they are working hard behind the scenes to get traction with the CDC. The HP should be the go-to treatment for any pregnant woman who contracts Zika.
I'll be interested to see whether this gets picked up by the more mainstream media. Donbass News International smells a bit like a propaganda arm for someone -- Russia? -- although it's difficult to tell for sure.
On the other hand, if it's true, well, then I recommend "The Stand" by Stephen King. Move to Boulder NOW (or Vegas if that's your thing).
We're now at the end of the two month window when JJ said the CTE manuscript would drop. I hope it hits tomorrow and the shorts lose their shorts.
If you go to his CTE page you can read a little more on the study. http://www.sternneurolab.org/chronic-traumatic-encephalopathy/ (Scroll down to the "Biomarkers, Risk, Assessment, and Imaging Network for CTE" section.)
Dr. Stern is the contact PI (other PI’s are J. Cummings, E. Reiman, and M. Shenton) of a $16.7 million, multicenter, multidisciplinary, 7-year grant to further his initial work on the development of in vivo biomarkers for chronic traumatic encephalopathy (CTE) and clinical diagnostic criteria for CTE. At the time of this writing, the grant proposal has been selected for funding by NINDS and has been approved by Council. Former NFL players, former college football players, and "control" participants will be recruited for examinations to be held at one of four locations (Boston, New York, Las Vegas, Scottsdale/Pheonix).
Considering ESI holds some significant patents on removing exosomes from the bloodstream, I can't imagine how Aethlon/ESI wouldn't be involved.
I'd say the chance is better than 50/50 that those indulging in tax-loss selling are going to get bitten in the behind. The CTE data release could be a game changer, and if it's published this month, it will be hard to get into AEMD for less than $10.
Nope. In fact, no Aethlon targets have disappeared. The Hemopurifier is an adjunct therapy. New drug? Aethlon's HP can help make it better. New vaccine? Aethlon's HP can offer help to the 5, 10, or 40 percent for whom the vaccine is ineffective.
It's an adjunct therapy, it's not a cure for anything and it's never been advertised as such except for those who don't understand the technology's value.
I foresee that this could bring a few more dollars to Aethlon's coffers:
NEW "Biomarkers, Risk, Assessment, and Imaging Network for CTE"
Dr. Stern is the contact PI (other PI’s are J. Cummings, E. Reiman, and M. Shenton) of a $16.7 million, multicenter, multidisciplinary, 7-year grant to further his initial work on the development of in vivo biomarkers for chronic traumatic encephalopathy (CTE) and clinical diagnostic criteria for CTE. At the time of this writing, the grant proposal has been selected for funding by NINDS and has been approved by Council. Former NFL players, former college football players, and "control" participants will be recruited for examinations to be held at one of four locations (Boston, New York, Las Vegas, Scottsdale/Pheonix).
*************
This is Boston University's follow on study to DETECT.
ADAPT has been around for a number of years. I think until now, however, they haven't had a clear idea of how to get the marketplace to recognize its value.
That market forecast also raises the possibility of one (or more!) of those larger players making a move on Exosome Sciences. ESI holds some very valuable patents that could be key to creating a mechanism for cancer diagnosis and treatment.
I sense a pump coming as a result of this article (great read, by the way). A lot of Twitter chatter from names I haven't seen before.
Apparently this seemed like just a really, really good time to hand out $200K in retention bonuses to the top players.
http://www.sec.gov/Archives/edgar/data/882291/000101968715003774/aethlon_8k.htm
Since we're all left here to read the tea leaves, I do find it interesting that Aethlon is choosing to pound the CTE issue with Tweets. Does that foreshadow some outstanding results from their research with BU, do you suppose?
DaVita buying Everett Clinic
Just saw this article. It includes a nice plug for Aethlon. http://finance.yahoo.com/news/davita-boost-operating-capacity-everett-173505888.html
It's not an either-or situation. Battelle, Wyss, NxStage, Cytosorbents, and Aethlon have all been getting pieces of the same pie and they're all working toward the same goal.
There are a thousand things going on behind the curtains that we'll never know about.
News from the presentation....
Some nice revelations:
Among other topics discussed in the presentation, Mr. Joyce provided a brief update on near term corporate objectives identified during the Company’s earnings release call held on August 13, 2015, as follows:
· The Company has received verbal confirmation from the Defense Advanced Research Projects Agency (DARPA) that its multi-year contract with DARPA will be renewed for an additional one-year period. While the Company has been informally advised that the contract will be renewed for the additional one-year period, there can be no assurance that written confirmation of renewal will be delivered to the Company or that the terms of the contract will not be modified.
· The Company has initiated its clinical study at the National Institute of Virology (NIV) in India to test the Aethlon Hemopurifier® as a candidate to treat Chikungunya, a debilitating mosquito borne virus. NIV is one of the major institutes of the Indian Council of Medical Research and is a World Health Organization collaborating center.
· The first patient has been enrolled in the Company’s cancer study at U.C. Irvine Medical Center in California. The study will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The study endpoints include establishing baseline exosome levels and monitoring changes in circulating exosome concentration associated with tumor treatment and the association of longitudinal changes in circulating exosome concentrations with response to treatment. The clinical study will also provide data to help direct future clinical investigations of the Aethlon Hemopurifier® as a therapeutic candidate to reduce the presence of circulating tumor-derived exosomes, which are known to suppress the immune system of cancer patients and contribute to the spread of metastasis.
· A manuscript has been submitted for potential publication relating to data from the “Diagnosing and Evaluating Traumatic Encephalopathy using Clinical Tests (DETECT)” study. The DETECT study examined potential biomarkers for Chronic Traumatic Encephalopathy (CTE) by studying a sample of former professional American football players and a control group of same-age men without any history of brain trauma from contact sport involvement. In connection with the DETECT study, researchers at Exosome Sciences, Inc. (the Company’s majority-owned subsidiary) have been applying proprietary techniques to isolate microscopic exosomes that transport CTE associated tau protein (tausomes) across the blood brain barrier.
Does anyone have any speculation as to the reason for the odd trading pattern that has developed over the last month? Is someone accumulating? ~81K shares traded, 48K of which was traded in the last 10 minutes. Those huge last-minute trades are becoming more common place.
And wouldn't it be funny if this movie is what gets Aethlon the attention it so richly deserves: http://www.hollywoodreporter.com/news/will-smiths-concussion-drama-nfls-820171
Two presentations within a day. Maybe JJ's planning on having something new to talk about.